Sulfuric Acids: Inorganic and organic derivatives of sulfuric acid (H2SO4). The salts and esters of sulfuric acid are known as SULFATES and SULFURIC ACID ESTERS respectively.Lathyrism: A paralytic condition of the legs caused by ingestion of lathyrogens, especially BETA-AMINOPROPIONITRILE or beta-N-oxalyl amino-L-alanine, which are found in the seeds of plants of the genus LATHYRUS.Sulfenic Acids: Oxy acids of sulfur with the general formula RSOH, where R is an alkyl or aryl group such as CH3. They are often encountered as esters and halides. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Aminoacetonitrile: Cyanomethylamine.Glycine: A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.Water: A clear, odorless, tasteless liquid that is essential for most animal and plant life and is an excellent solvent for many substances. The chemical formula is hydrogen oxide (H2O). (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Barium Sulfate: A compound used as an x-ray contrast medium that occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield.Moles: Any of numerous burrowing mammals found in temperate regions and having minute eyes often covered with skin.Ammonia: A colorless alkaline gas. It is formed in the body during decomposition of organic materials during a large number of metabolically important reactions. Note that the aqueous form of ammonia is referred to as AMMONIUM HYDROXIDE.Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous.Receptors, Tachykinin: Cell surface proteins that bind TACHYKININS with high affinity and trigger intracellular changes influencing the behavior of cells. Three classes of tachykinin receptors have been characterized, the NK-1; NK-2; and NK-3; which prefer, respectively, SUBSTANCE P; NEUROKININ A; and NEUROKININ B.Tachykinins: A family of biologically active peptides sharing a common conserved C-terminal sequence, -Phe-X-Gly-Leu-Met-NH2, where X is either an aromatic or a branched aliphatic amino acid. Members of this family have been found in mammals, amphibians, and mollusks. Tachykinins have diverse pharmacological actions in the central nervous system and the cardiovascular, genitourinary, respiratory, and gastrointestinal systems, as well as in glandular tissues. This diversity of activity is due to the existence of three or more subtypes of tachykinin receptors.Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI.Receptors, Neurokinin-2: A class of cell surface receptors for tachykinins that prefers neurokinin A; (NKA, substance K, neurokinin alpha, neuromedin L), neuropeptide K; (NPK); or neuropeptide gamma over other tachykinins. Neurokinin-2 (NK-2) receptors have been cloned and are similar to other G-protein coupled receptors.Substance P: An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of PAIN, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses.Receptors, Neurokinin-3: A class of cell surface receptors for tachykinins that prefers neurokinin B (neurokinin beta, neuromedin K) over other tachykinins. Neurokinin-3 (NK-3) receptors have been cloned and are members of the G-protein coupled receptor superfamily. They have been found in the central nervous system and in peripheral tissues.Neurokinin-1 Receptor Antagonists: Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.Neurokinin B: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ A with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the URINARY BLADDER and UTERUS.Receptors, Neurokinin-1: A class of cell surface receptors for TACHYKININS with a preference for SUBSTANCE P. Neurokinin-1 (NK-1) receptors have been cloned and are members of the G protein coupled receptor superfamily. They are found on many cell types including central and peripheral neurons, smooth muscle cells, acinar cells, endothelial cells, fibroblasts, and immune cells.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Cell Adhesion Molecules: Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Waiting Lists: Prospective patient listings for appointments or treatments.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Phosphatidylcholines: Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a choline moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and choline and 2 moles of fatty acids.Phosphatidylethanolamines: Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to an ethanolamine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and ethanolamine and 2 moles of fatty acids.Life Tables: Summarizing techniques used to describe the pattern of mortality and survival in populations. These methods can be applied to the study not only of death, but also of any defined endpoint such as the onset of disease or the occurrence of disease complications.Small Molecule Libraries: Large collections of small molecules (molecular weight about 600 or less), of similar or diverse nature which are used for high-throughput screening analysis of the gene function, protein interaction, cellular processing, biochemical pathways, or other chemical interactions.Kinetics: The rate dynamics in chemical or physical systems.Phospholipids: Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.

Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. (1/44)

Cotreatment with a minimally toxic concentration of the protein kinase C (PKC) activator (and down-regulator) bryostatin 1 (BRY) induced a marked increase in mitochondrial dysfunction and apoptosis in U937 monocytic leukemia cells exposed to the proteasome inhibitor lactacystin (LC). This effect was blocked by cycloheximide, but not by alpha-amanitin or actinomycin D. Qualitatively similar interactions were observed with other PKC activators (eg, phorbol 12-myristate 13-acetate and mezerein), but not phospholipase C, which does not down-regulate the enzyme. These events were examined in relationship to functional alterations in stress (eg, SAPK, JNK) and survival (eg, MAPK, ERK) signaling pathways. The observations that LC/BRY treatment failed to trigger JNK activation and that cell death was unaffected by a dominant-interfering form of c-JUN (TAM67) or by pretreatment with either curcumin or the p38/RK inhibitor, SB203580, suggested that the SAPK pathway was not involved in potentiation of apoptosis. In marked contrast, perturbations in the PKC/Raf/MAPK pathway played an integral role in LC/BRY-mediated cell death based on evidence that pretreatment of cells with bisindolylmaleimide I, a selective PKC inhibitor, or geldanamycin, a benzoquinone ansamycin, which destabilizes and depletes Raf-1, markedly suppressed apoptosis. Furthermore, ERK phosphorylation was substantially prolonged in LC/BRY-treated cells compared to those exposed to BRY alone, and pretreatment with the highly specific MEK inhibitors, PD98059, U0126, and SL327, opposed ERK activation while protecting cells from LC/BRY-induced lethality. Together, these findings suggest a role for activation and/or dysregulation of the PKC/MAPK cascade in modulation of leukemic cell apoptosis following exposure to the proteasome inhibitor LC. (Blood. 2001;97:2105-2114)  (+info)

Alcohol-induced c-Fos expression in the Edinger-Westphal nucleus: pharmacological and signal transduction mechanisms. (2/44)

Mapping inducible transcription factors has shown that the Edinger-Westphal nucleus is preferentially sensitive to alcohol intoxication. Herein, we characterize the pharmacological and signal transduction mechanisms related to alcohol-induced c-Fos expression in Edinger-Westphal neurons. Using immunohistochemistry, we show that pretreatment with gamma-aminobutyric acid (GABA)-ergic antagonists (4 mg/kg bicuculline and 45 mg/kg pentylenetetrazole) attenuates induction of c-Fos expression by alcohol (2.4 g/kg, intraperitoneal). In addition, 10 mg/kg 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)4,5-dihydro-1H-imidazole (RX 821002), an alpha(2A/D)-adrenoceptor antagonist, and 20 mg/kg haloperidol, a dopamine antagonist, also block alcohol-induced c-Fos expression in Edinger-Westphal neurons. No effects were seen in alcohol-induced c-Fos after the pretreatment of 20 mg/kg propranolol (beta-adrenoceptor antagonist), 10 mg/kg 2-(2-(4-(2-methoxyphenyl)piperazin-1-yl) ethy)-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride (ARC 239) (alpha(2B/C)-adrenoceptor antagonist), or 30 mg/kg naltrexone (opioid antagonist). Although positive modulators for the GABA(A) receptor (20 mg/kg 3alpha-hydroxy-5alpha-pregnan-20-one and 10-30 mg/kg chlordiazepoxide) and opioid receptor (10 mg/kg morphine) produced significant elevations, agonists for alpha(2)-adrenoceptors (clonidine) and dopamine receptors (apomorphine) had no effect on Edinger-Westphal c-Fos expression. These findings suggest that alcohol-induced c-Fos expression in Edinger-Westphal results from direct interactions with GABA(A) receptors, which are modified by alpha(2A/D)-adrenoceptors and dopamine receptors. Also using immunohistochemistry to identify potential intracellular mechanisms associated with alcohol-induced c-Fos expression in Edinger-Westphal, we show time-dependent increases in serine 727 phospho-signal transducer and activator of transcription 3 (Stat3) but no changes in phospho-cAMP response element-binding protein and phospho-Elk1. Time-dependent increases in phospho-extracellular signal-regulated kinase (ERK) 1/2 were found to occur simultaneously with increases in serine 727 phospho-Stat3. Finally, blockade of ERK 1/2 phosphorylation with the mitogen-activated protein kinase (MEK) 1/2 inhibitor SL327 blocked alcohol-induced c-Fos expression, suggesting that alcohol induces c-Fos in Edinger-Westphal neurons through activation of the MEK1/2-ERK1/2-Stat3 pathway.  (+info)

Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. (3/44)

MEK1/2 is a serine/threonine protein kinase that phosphorylates and activates extracellular signal-responsive kinase (ERK)1/2. In the present study we explored the role of MEK1/2 in ischemic brain injury using a selective MEK1/2 inhibitor, SL327, in mice. C57BL/6 mice were subjected to a 30-min occlusion of the middle cerebral artery (MCAO) followed by reperfusion. Western blot analysis demonstrated the immediate activation of MEK/ERK after reperfusion (within the first 10 min) in the ischemic brain; this activation was dose dependently blocked by SL327 (10-100 mg/kg, i.p.). A single dose of SL327 (100 mg/kg) administered 15 min before or 25 min after the onset of ischemia resulted in 63.6% (n = 18, p < 0.001) and 50.7% (n = 18, p < 0.01) reduction in infarct size, respectively, compared with vehicle-treated mice. Similarly, SL327 significantly reduced neurological deficits 1 to 3 days after reperfusion (n = 12, p < 0.01). The salutary effect of SL327-induced neuroprotection was independent of mitochondrial cytochrome c release or caspase-8-mediated apoptosis; however, SL327 markedly suppressed the levels of active caspase-3 and DNA fragmentation (as a measure of apoptosis) after ischemia/reperfusion. Our data suggest that the inhibition of MEK1/2 results in neuroprotection from reperfusion injury and that this protection may be associated with the reduction in apoptosis.  (+info)

A role for ERK MAP kinase in physiologic temporal integration in hippocampal area CA1. (4/44)

Recent studies demonstrate a requirement for the Extracellular signal Regulated Kinase (ERK) mitogen-activated protein kinase (MAPK) cascade in both the induction of long-lasting forms of hippocampal synaptic plasticity and in hippocampus-dependent associative and spatial learning. In the present studies, we investigated mechanisms by which ERK might contribute to synaptic plasticity at Schaffer collateral synapses in hippocampal slices. We found that long-term potentiation (LTP) induced with a pair of 100-Hz tetani does not require ERK activation in mice whereas it does in rats. However, in mice, inhibition of ERK activation blocked LTP induced by two LTP induction paradigms that mimicked the endogenous theta rhythm. In an additional series of studies, we found that mice specifically deficient in the ERK1 isoform of MAPK showed no impairments in tests of hippocampal physiology. To investigate ERK-dependent mechanisms operating during LTP-inducing stimulation paradigms, we monitored spike production in the cell body layer of the hippocampus during the period of theta-like LTP-inducing stimulation. Theta-burst stimulation (TBS) produced a significant amount of postsynaptic spiking, and the likelihood of spike production increased progressively over the course of the three trains of TBS independent of any apparent increase in Excitatory Post-Synaptic Potential (EPSP) magnitude. Inhibition of ERK activation dampened this TBS-associated increase in spiking. These data indicate that, for specific patterns of stimulation, ERK may function in the regulation of neuronal excitability in hippocampal area CA1. Overall, our data indicate that the progressive increase in spiking observed during TBS represents a form of physiologic temporal integration that is dependent on ERK MAPK activity.  (+info)

Preparation of (cyanomethylene)trimethylphosphorane as a new Mitsunobu-type reagent. (5/44)

(Cyanomethylene)trimethylphosphorane (CMMP) mediates Mitsunobu-type reactions, which are a versatile method for the alkylation of various nucleophiles (HA) with alcohols (ROH) to give RA. CMMP is quite effective for the reaction of carbon nucleophiles whose pK(a) value are higher than 13. CMMP, which is very sensitive to air and moisture, was synthesized in two steps starting from chloroacetonitrile.  (+info)

The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. (6/44)

The neurobiological underpinnings of mood modulation, molecular pathophysiology of manic-depressive illness, and therapeutic mechanism of mood stabilizers are largely unknown. The extracellular signal-regulated kinase (ERK) pathway is activated by neurotrophins and other neuroactive chemicals to produce their effects on neuronal differentiation, survival, regeneration, and structural and functional plasticity. We found that lithium and valproate, commonly used mood stabilizers for the treatment of manic-depressive illness, stimulated the ERK pathway in the rat hippocampus and frontal cortex. Both drugs increased the levels of activated phospho-ERK44/42, activated phospho-ribosomal protein S6 kinase-1 (RSK1) (a substrate of ERK), phospho-CREB (cAMP response element-binding protein) and phospho-B cell lymphoma protein-2 antagonist of cell death (substrates of RSK), and BDNF. Inhibiting the ERK pathway with the blood-brain barrier-penetrating mitogen-activated protein kinase (MAP kinase)/ERK kinase (MEK) kinase inhibitor SL327, but not with the nonblood-brain barrier-penetrating MEK inhibitor U0126, decreased immobility time and increased swimming time of rats in the forced-swim test. SL327, but not U0126, also increased locomotion time and distance traveled in a large open field. The behavioral changes in the open field were prevented with chronic lithium pretreatment. SL327-induced behavioral changes are qualitatively similar to the changes induced by amphetamine, a compound that induces relapse in remitted manic patients and mood elevation in normal subjects. These data suggest that the ERK pathway may mediate the antimanic effects of mood stabilizers.  (+info)

Sustained extracellular signal-regulated kinase 1/2 phosphorylation in neonate 6-hydroxydopamine-lesioned rats after repeated D1-dopamine receptor agonist administration: implications for NMDA receptor involvement. (7/44)

Extracellular signal-regulated kinase (ERK) 1/2, a well known regulator of gene expression, is likely to contribute to signaling events underlying enduring neural adaptations. Phosphorylated (phospho)-ERK was examined immunohistochemically after both single and repeated (i.e., sensitizing) doses of the partial D1-dopamine (DA) receptor agonist SKF-38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benazepine HCl) to adult rats lesioned as neonates (neonate lesioned) with 6-hydroxydopamine. Remarkably, prolonged phospho-ERK accumulated primarily in layers II-III of medial prefrontal cortex (MPC), where it declined gradually yet remained significantly elevated for at least 36 d after repeated doses of SKF-38393. Sustained (> or =7 d) phospho-ERK was observed for shorter periods in various other cortical regions but was not detectable in striatum or nucleus accumbens. At 36 d, an additional injection of SKF-38393 to sensitized rats restored phospho-ERK to maximal levels only in MPC when examined 7 d later. Phosphorylated cAMP response element-binding protein (CREB), examined 7 d after the sensitizing regimen, was observed exclusively in MPC, where it was abundant throughout all layers. Systemic injections of SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitri le), an inhibitor of the upstream ERK activator mitogen ERK kinase, attenuated both ERK and CREB phosphorylation in layers II-III of MPC. Pretreatment with the D1 antagonist SCH-23390 ((R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-OL maleate) inhibited the prolonged increase in MPC phospho-ERK, whereas the 5-HT2 receptor antagonist ketanserin (3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione tartrate) was ineffective. Competitive and noncompetitive NMDA receptor antagonists also blocked sustained ERK phosphorylation. Collectively, the present results demonstrate coupling of D1 and NMDA receptor function reflected in sustained activation of the ERK signaling pathway in MPC of SKF-38393-sensitized neonate-lesioned rats. Ultimately, long-lasting phosphorylation of ERK and CREB in MPC may play a pivotal role in any permanent adaptive change(s) in these animals.  (+info)

ERK kinase inhibition stabilizes the aryl hydrocarbon receptor: implications for transcriptional activation and protein degradation. (8/44)

The ultimate carcinogen and metabolite of benzo-[a]pyrene-7,8-dihydrodiol, benzo[a]pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide (+/-), stimulates apoptosis, and this process can be blocked by extracellular signal-regulated kinase (Erk) kinase inhibitors. However, we show here that Erk kinase inhibitors were unable to prevent B[a]P-7,8-dihydrodiol-induced apoptosis, leading us to speculate that Erk kinases are linked to regulation of the aryl hydrocarbon (Ah) receptor. Cotreatment of hepa1c1c7 cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Erk kinase inhibitor PD98059, U0126, or SL327 led to enhanced nuclear accumulation of Ah receptor but with a reduced capacity to complement TCDD induction of Cyp1a1. This is explained in part by the ability of Erk kinase inhibitors to alter the steady-state levels of cellular Ah receptor, a result that leads to a dramatic induction in detectable receptor levels. These changes in cellular Ah receptor levels are associated with delayed degradation of the Ah receptor because TCDD-initiated degradation is reversed when cells are co-treated with TCDD and Erk kinase inhibitors. Erk kinase is linked to Ah receptor expression, as demonstrated by reductions in total Ah receptor levels after overexpression of constitutively active MEK1. In addition, Erk kinase activity modulates the transcriptional response because MEK1 overexpression enhances TCDD-initiated transactivation potential of the receptor. Thus, Erk kinase activity facilitates ligand-initiated transcriptional activation while targeting the Ah receptor for degradation. Immunoprecipitation experiments of the Ah receptor indicate that Erk kinase activity is associated with the receptor. It is interesting that the carboxyl region of the Ah receptor is associated with the transactivation region as well as the site for ubiquitination, indicating that Erk kinase-dependent phosphorylation targets the carboxyl region of the receptor.  (+info)

*Aminoacetonitrile

H2O The aminoacetonitrile can be hydrolysed to give glycine: Aminoacetonitrile derivatives are useful antihelmintics. They act ... In 2008, aminoacetonitrile was discovered in the Large Molecule Heimat, a giant gas cloud near the galactic center in the ... Aminoacetonitrile is a simple organic compound containing both nitrile and amino groups. It is somewhat similar to the simplest ... Industrially aminoacetonitrile is produced from glycolonitrile by reaction with ammonia: HOCH2CN + NH3 → H2NCH2CN + ...

*Anthelmintic

This is especially true of nematodes, and has helped spur development of aminoacetonitrile derivatives for treatment against ... effective against a variety of gastrointestinal helminths Aminoacetonitrile derivatives e.g., Monepantel : effective against a ...

*Ethanimine

Experimental investigation of nitrile formation from VUV photochemistry of interstellar ices analogs: acetonitrile and amino acetonitrile ...

*List of interstellar and circumstellar molecules

2008), "Detection of amino acetonitrile in Sgr B2(N)", Astronomy & Astrophysics, 482: 179-196, arXiv:0801.3219 , Bibcode:2008A& ...

*Large Molecule Heimat

Many species of molecule, including aminoacetonitrile (a molecule related to glycine), ethyl formate, and butyronitrile, have ...

*Glycine

In 2008, the Max Planck Institute for Radio Astronomy discovered the glycine-like molecule aminoacetonitrile in the Large ...

*List of MeSH codes (D02)

... aminoacetonitrile MeSH D02.640.529.175 --- chloramphenicol MeSH D02.640.529.175.850 --- thiamphenicol MeSH D02.640.529.240 --- ...

*Glycolonitrile

... can react with ammonia to give aminoacetonitrile, which can be hydrolysed to give glycine: HOCH2CN + NH3 → ...
... SOUTH SAN FRANCISCO Calif. May 6 /- CatalystBiosci...CB 813 is designed to substantially enhance clot-generating activity a... Patients receiving factor VIIa therapy typically require multipledos... The selection of this development candidate is an exciting milestone...,Catalyst,Biosciences,Selects,Drug,Development,Candidate,in,Factor,VIIa,Program,for,Hemophilia,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate (DC) for ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in development for the treatment of AAT deficiency-associated liver disease. New pre-clinical data were presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW), held May 3 - 6, 2014 in Chicago, Illinois. ALN-AAT is one of Alnylams genetic medicine programs, which are RNAi therapeutics directed toward genetically defined targets for the treatment of diseases with high unmet medical need. AAT deficiency-associated liver disease is caused by accumulation of mutant AAT protein ("Z-allele" or "Z-AAT") in liver tissue with subsequent liver injury, fibrosis, cirrhosis, and, in some cases, hepatocellular carcinoma. It is estimated that approximately 12,000 people with AAT deficiency in the U.S. and E.U. have associated liver pathology. The company now plans to initiate ...
When contemplating how best to cripple this pathway, several key proteins are reasonable candidates for consideration. Most efforts to design small-molecule inhibitors of RAS-MAPK signaling have focused on the major protein players (i.e., RAS, RAF, MEK, and ERK). We may see more attention devoted in the future, however, to several scaffolding proteins and endogenous inhibitors that also come into play with respect to pathway dynamics (5). Recent advances in the development of genome-wide RNA interference libraries have enabled screening that may potentially identify other novel regulators of MAP signaling amenable to pharmacologic intervention (6, 7).. Is RAS druggable? Attempts to target RAS by perturbing its interaction with either SOS or GRB2 have not yielded viable drug development candidates largely because of the inherent difficulties of disrupting protein-protein interactions with drug-like molecules. Several drug discovery programs have also been devoted to finding inhibitors of ...
VX 954 was selected in October 2000 as a drug development candidate from Vertex Pharmaceuticals p38 mitogen-activated protein (MAP) kinase research programme.
Roche/ Discuva: Roche and U.K. biotech Discuva are collaborating on the discovery and development of new antibiotics to treat multi-drug resistant gram-negative infections using Discuvas Selective Antibiotic Target Identification technology platform. SATI uses next-generation sequencing and bioinformatics to identify bacterial targets and select from among them promising drug development candidates. The deal, announced on Feb. 28, fits well with Roches revamped research strategy in infectious diseases, a field its R&D organization exited more than 20 years ago, but recently has re-entered. The new, narrower focus is on multi-drug resistant, pathogen-specific, hospital-directed therapies, rather than broad spectrum antibiotics that were Roches original focus. Companion diagnostics, an area of strength due to Roches long experience in molecular diagnostics, will be important in identifying pathogens. In an October 2013 meeting in New York, Roches head of research and early-stage development ...
NewLink Genetics Corporation (NASDAQ NLNK) today announced that indoximod, its leading drug development candidate, was granted orphan-drug designation by the U.
... - RDEA594 Data to Be Presented at the 2008 Annual European Congress... 2008 - ...SAN DIEGO May 19 /- Ardea Biosciences Inc.(N...Based on extensive in vitro and in vivo experiments the Companybelie...,Ardea,Biosciences,Identifies,Lead,Development,Candidate,for,Gout,,RDEA594,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Array Receives $1,000,000 Milestone Payment from AstraZeneca -. BOULDER, Colo., Jan. 24 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY) and AstraZeneca PLC selected an additional clinical candidate for their small molecule anti-cancer program, triggering a $1 million milestone payment from AstraZeneca to Array. In December 2003, Array partnered the oncology portion of its MEK program, including its lead compound, ARRY-142886 (AZD6244), for co-development and commercialization with AstraZeneca. At that time, Array and AstraZeneca established a collaboration for research and development of additional clinical candidates.. "We are pleased that our collaboration with AstraZeneca has yielded an additional high quality development candidate," said Kevin Koch, Ph.D., President and Chief Scientific Officer, Array BioPharma. "Our first proprietary compound, ARRY-142886, continues to make good progress in Phase Ib. We believe the data generated in this study will support more advanced ...
Basel (Switzerland) and Mannheim (Germany), January 18, 2018 - VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company will participate in several upcoming events in the first quarter of 2018.. ASCO-SITC Clinical Immuno-Oncology Symposium January 25-27, 2018 San Francisco, CA, USA. The ASCO-SITC Clinical Immuno-Oncology Symposium is focused on clinical and translational research in immuno-oncology and the implications for clinical care. VAXIMM will present preclinical data with its oral T‑cell immunotherapy development candidate VXM10. The poster, "Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD‑L1," summarizes the immunogenicity and anti-leukemia activity of VXM10 in an animal model, transformed with a eukaryotic expression plasmid encoding different variants of the murine PD‑L1 protein.. The poster will be presented during Poster Session A on Thursday, January 25th at 11:30 AM - ...
Worldwide the incidence for NAFLD is rising dramatically and is highly correlated to the Metabolic Syndrome. Activation of the FXR recep¬tor through a drug combats the underlying causes of NAFLD by lowering liver lipids and improving hepatic insulin sensitivity, combined with a liver specific anti-fibrotic and anti-inflammatory effect. A first human clinical trial with Phenex´ proprietary FXR development candidate PX-102 is scheduled for spring 2011. Phenex intends to outlicense this program after first human proof of concept data ...
Continued Productivity in Research. Vertex continues to focus its research efforts in the areas of infectious diseases, including viral infections - such as influenza - and bacterial infections, inflammatory diseases, cancer and neurological disorders, including pain. Vertex expects additional development candidates for the treatment of one or more of these diseases to emerge from research in 2012. The company will report full-year 2011 financial results and financial guidance on February 2, 2012 . Webcast. Vertex Pharmaceuticals will webcast its corporate presentation at the 30th Annual J.P. Morgan Healthcare Conference on January 9, 2012 at 11:00 a.m. PT ( 2:00 p.m. ET ). A link to the live webcast will be available via Vertexs website, www.vrtx.com, in the Events & Presentations section. An archived webcast of the presentation will be available on Vertexs website through January 23, 2012 . About Vertex. Vertex creates new possibilities in medicine. Our team discovers, develops and ...
Max and Dev have developed a powerful platform for fine-tuning the tumor microenvironment to enhance the immune systems response against cancer," said Steven James, Pionyrs executive chairman and interim CEO. "We are building on these capabilities to develop antibody-based therapeutics with novel antigen targets and mechanisms of action. We expect to choose development candidates and drive them to IND in the near future.". Pionyr Immunotherapeutics is led by industry veterans with deep management and immuno-oncology expertise. Mr. James, former CEO of Labrys Biologics (acquired by TEVA) and KAI Pharmaceuticals (acquired by Amgen), is joined on the leadership team by Michel Streuli, Ph.D., senior vice president of research, who previously led immuno-oncology efforts at Gilead, Merck (as early development chair for Keytruda), Schering-Plough and Organon. On the board of directors, in addition to Mr. James and Dr. Krummel, are Michael Ross, Ph.D., and Joshua Resnick, M.D., both partners at SV ...
1HV7: The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate
WASHINGTON, April 1, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported updated Phase 1 clinical data for IPI-549, an orally administered immuno-oncology development candidate ...
Highlights Breadth, Depth and Velocity of Development Pipeline-- 12 mRNA development candidates across three therapeutic areas - infectious diseases, immuno-oncology and cardiovascular disease Five clinical studies underway; 332 subjects dosed to date
Macrophage Pharma is developing a highly novel class of small molecule therapeutics which modulate immune responses to combat cancer based on its proprietary Esterase Motif Technology™ (ESM™) platform. ESM molecules deliver small molecule inhibitors of key intracellular targets in a highly selective manner to macrophages, monocytes and monocyte-derived dendritic cells. Macrophage Pharma is rapidly progressing its lead molecules to the clinic utilising ESM to deliver inhibitors to tumour associated macrophages and tolerogenic dendritic cells in the tumour microenvironment.. The Company was founded by the CRT Pioneer Fund and recently announced a £9 million financing round. The round was led by CPF who were joined by two specialist investors, Novo A/S and Aglaia Biomedical Ventures BV. The proceeds of the financing round will enable the Company to complete the pre-clinical development of its lead development candidate, a p38 MAP kinase inhibitor, and advance two additional discovery ...
About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The companys lead product candidate, CRN00808, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics second oral product development candidate, CRN01941, has entered the clinic for the treatment of neuroendocrine tumors. The company is also developing oral nonpeptide somatostatin agonists for hyperinsulinism, as well as oral nonpeptide ACTH antagonists for the treatment of Cushings disease. All of the companys drug candidates are new chemical entities resulting from in-house drug discovery efforts. For more information, please visit www.crinetics.com. Forward-Looking Statements ...
Pegoraro S, Duffey M, Otto TD, Wang Y, Rosemann R, Baumgartner R, Fehler SK, Lucantoni L, Avery VM, Moreno-Sabater A, Mazier D, Vial HJ, Strobl S, Sanchez CP, Lanzer M (2017). SC83288 is a clinical development candidate for the treatment of severe malaria. Nat Commun. 8:14193. Cyrklaff M, Srismith S, Nyboer B, Burda K, Hoffmann A, Lasitschka F, Adjalley S, Bisseye C, Simpore J, Mueller AK, Sanchez CP, Frischknecht F, Lanzer M (2016). Oxidative insult can induce malaria-protective trait of sickle and fetal erythrocytes. Nat Commun. 7:13401. Rieger H, Yoshikawa HY, Quadt K, Nielsen MA, Sanchez CP, Salanti A, Tanaka M, Lanzer M (2015). Cytoadhesion of Plasmodium falciparum-infected erythrocytes to chondroitin-4-sulfate is cooperative and shear enhanced. Blood 125:383-391. Sanchez CP, Liu CH, Mayer S, Nurhasanah A, Cyrklaff M, Mu J, Ferdig MT, Stein WD, Lanzer M (2014). A HECT ubiquitin-protein ligase as a novel candidate gene for altered quinine and quinidine responses in Plasmodium falciparum. ...
NovaDigm is developing innovative immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial disease, which can be recurrent, drug-resistant and in some cases, life-threatening. NovaDigms lead development candidate, NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, including nosocomial candidiasis, a severe life threatening infection and Staphylococcus aureus, including MRSA. ...
Michael Waring is a Principal Scientist in the Oncology medicinal chemistry group at AstraZeneca. He earned his PhD from the University of Manchester under the supervision of Prof. Timothy Donohoe (1999) followed by postdoctoral research with Prof. Philip Magnus at the University of Texas at Austin. Mike joined AstraZeneca in 2001 and has worked on projects at all stages of drug discovery across both oncology and cardiovascular disease areas, culminating in the discovery of 14 development candidates, including AZD9291. From summer 2015 will be Professor of Medicinal Chemistry at Newcastle University ...
购买MMP3小鼠单克隆抗体[SL-1 ID3](ab3204),MMP3抗体经WB,ICC/IF验证,可与人样本反应。产品出库一年都在质保范围内。中国现货速达。
The EM Radiation Research Trust is an independent body. The aim of the organisation is to provide the facts about electro-magnetic radiation and our health to the public and the media.. Follow us on:. ...
This study examined the development of resistance to anthelmintics in Haemonchus contortus in lambs under suppressive or selective treatment regimens that included monepantel. Twenty Ile de France and 20 Santa Ines lambs were allocated to two anthelmintic treatment regimens, based on body weight and nematode faecal egg counts (FEC): targeted selective treatment (TST) or suppressive treatment, both with monepantel. Lambs of the TST group were treated individually when they presented with a packed cell volume (PCV) ≤20%. On 7 October 2016, the lambs were allocated to clean pastures, where they grazed in separated paddocks by group until late February 2017. The experimental area was contaminated with nematodes that were introduced with the experimental Ile de France and Santa Ines lambs, naturally infected with gastrointestinal nematodes. To maintain the grazing lambs in the suppressive treatment group and their pasture as free of worms as possible, these lambs were treated with anthelmintics before
approved drugs in the high need areas of pain, ADHD and other central nervous system disorders. KemPharms co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release profiles for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the companys immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on ...
This is the first monoclonal antibody encoded by mRNA to be dosed in a human and the first development candidate from the Companys systemic therapeutics modalities to start clinical testing.. We believe this trial will give us important information about how mRNA may be used to make systemically-available complex therapeutic proteins in a consistent, dose-dependent fashion," said Tal Zaks, M.D., Ph.D., chief medical officer at Moderna. "Dosing the first monoclonal antibody encoded by mRNA in humans is a significant milestone for our team and mRNA platform. We look forward to learning about the functionality of our mRNA-encoded antibody in neutralizing the Chikungunya virus.". mRNA-1944 encodes a fully human IgG antibody originally isolated from B cells of a patient with a prior history of potent immunity against Chikungunya infection. It is composed of two mRNAs that encode the heavy and light chains of this anti-Chikungunya antibody within Modernas proprietary lipid nanoparticle (LNP) ...
Our overall theme and objective of this Center is to develop new classes of host-targeting antiviral therapeutics that are capable of treating multiple NIAID Emerging and Re-emerging Priority Pathogen viruses, when used alone or in combination with other available agents. The range of planned activities spans the translational development spectrum: from generating new host target focused leads, to validating promising lead molecules, and advancing optimized leads. We hypothesize that a collection of exciting preliminary datasets now offer the potential to be collaboratively translated into the development of novel broad spectrum antivirals. More specifically, we will test the following hypotheses: 1) human haploid genetic screens can identify novel host genes required for multiple RNA viruses, and recombinant AAV viral vectors can both validate these targets and serve as development candidates against the identified genes;2) a suite of novel computational methods can identify compounds with ...
PTC Therapeutics just selected a development candidate in its spinal muscular atrophy collaboration with Roche and the SMA Foundation, triggering a $10 million payment to PTC from Roche.
Homology Medicines, Inc., a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients, announced today the closing of an $83.5 million Series B financing led by Deerfield Management. New investors include Fidelity Management and Research Company, HBM Healthcare Investments, Maverick Ventures, Novartis, Rock Springs Capital, Vida Ventures, Vivo Capital and Alexandria Venture Investments. Existing investors 5AM Ventures, ARCH Venture Partners and Temasek also participated in the financing. Homology has raised $127 million since the Company launched in 2016. The proceeds from the Series B are expected to be used to advance Homologys lead development candidate that is currently in preclinical IND-enabling studies for an inborn error of metabolism disease. The proceeds are also expected to support continued work to progress Homologys AMEnDR™ (AAV-Mediated Editing by Direct Homologous Recombination) technology into the clinic ...
PALATINE, IL -- (Marketwired) -- 08/15/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today preliminary discussions from a meeting held with the U.S. Food and Drug Administration (FDA) regarding the development pathway for Acuras AVERSION® hydrocodone with acetaminophen tablet development candidate, which is intended to provide abuse-deterrent features to address abuse by nasal snorting and injection. In a May 2014 letter to Acura, FDA questioned the relevance of abuse of hydrocodone with acetaminophen products by nasal snorting after reviewing clinical and epidemiology data submitted by Acura. The FDA continues to question the relevance of abuse of hydrocodone with acetaminophen products by the intranasal route of administration and suggested additional information may help better inform their decision. The FDA indicated in the discussions that Acura may conduct an additional nasal abuse liability study for its AVERSION hydrocodone with acetaminophen product candidate, the ...
2JC0: Optimization of Novel Acyl Pyrrolidine Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase Leading to a Development Candidate.
B) Preparation of Glycine.-To a boiling suspension of 253 g. (0.8 mole) of barium hydroxide octahydrate in 500 cc. of water in a 1-l. beaker is added, in portions, 61.6 g. (0.4 mole) of aminoacetonitrile hydrogen sulfate at such a rate that the mixture does not froth over. The beaker is then covered with a 1-l. round-bottomed flask containing cold running water, and boiling is continued until no more ammonia is evolved. This requires six to eight hours. The barium is then quantitatively precipitated by the addition of exactly the necessary amount of 50 per cent sulfuric acid (Note 5). The filtrate is concentrated on a water bath to a volume of 50-75 cc.; on chilling, crude glycine crystallizes and is filtered off. The filtrate is again concentrated and chilled and the crystals removed. This process is continued until the final filtrate amounts to about 5 cc. The yield of crude glycine so obtained amounts to 25-27 g. This is systematically recrystallized from water, decolorizing with Norite and ...
Metals are recovered from ore concentrates by dry grinding, followed by a 2-stage leach process. The ground concentrate is leached with h2so4 at 90 deg-100 deg c to selectively remove ni and fe. The residue is then leached with h2so4 containing naocl or h2o2 to extract pt, pd, cu, and au. Thus, a flotation concentrate was smelted at 1,450 deg-1,600 deg c for 0.5 H, yielding a matte containing p
Y-box binding protein-1 (YB-1) is the first reported oncogenic transcription factor to induce the tumor-initiating cell (TIC) surface marker CD44 in triple-negative breast cancer (TNBC) cells. In order for CD44 to be induced, YB-1 must be phosphorylated at S102 by p90 ribosomal S6 kinase (RSK). We therefore questioned whether RSK might be a tractable molecular target to eliminate TICs. In support of this idea, injection of MDA-MB-231 cells expressing Flag-YB-1 into mice increased tumor growth as well as enhanced CD44 expression. Despite enrichment for TICs, these cells were sensitive to RSK inhibition when treated ex vivo with BI-D1870. Targeting RSK2 with small interfering RNA (siRNA) or small molecule RSK kinase inhibitors (SL0101 and BI-D1870) blocked TNBC monolayer cell growth by similar to 100%. In a diverse panel of breast tumor cell line models RSK2 siRNA predominantly targeted models of TNBC. RSK2 inhibition decreased CD44 promoter activity, CD44 mRNA, protein expression, and mammosphere ...
The treatment currently involves a relatively large number of capsules, so dogs that are difficult to orally medicate wouldnt be great candidates," said Dr Frimberger. "But we are working on reformulating the drug to make it better tasting and easier to administer to dogs before the full trials commence next year.". The MPL program involves two consultations/treatments at the Animal Referral Hospital (ARH) in Homebush, NSW. Owners would have to transport their dogs to and from Homebush for the two treatments. PharmAust will cover all compassionate use program costs, including travel expenses to and from the ARH, as well as costs for the initial conventional chemotherapy treatment upon program completion.. For more information or to enrol, please contact Dr Angela Frimberger on [email protected] What is canine lymphoma? Cancer is the number one cause of death in dogs over the age of 2, with 25 per cent of deaths attributed to cancer¹. "Approximately one in four dogs and one in ...
As a narcotic, morphine can cause withdrawal symptoms if it is stopped too quickly. This selection from the eMedTV Web site outlines some symptoms of morphine withdrawal and emphasizes the importance of slowly weaning yourself off the medication.
We promote folkdancing and Folkmusic in Western Europe. We have a large sales division (international folkddance en folkmusic) with cds, dvds, books, written music, We promote American & English Country, Irish & Scottisch dance and music
We promote folkdancing and Folkmusic in Western Europe. We have a large sales division (international folkddance en folkmusic) with cds, dvds, books, written music, We promote American & English Country, Irish & Scottisch dance and music
The Edinger-Westphal nucleus (accessory oculomotor nucleus) is the parasympathetic pre-ganglionic nucleus that innervates the iris sphincter muscle and the ciliary muscle. Alternatively, the Edinger-Westphal nucleus is a term often used to refer to the adjacent population of non-preganglionic neurons that do not project to the ciliary ganglion, but rather project to the spinal cord, dorsal raphe nucleus, and lateral septal nuclei.[1] Unlike the classical preganglionic Edinger-Westphal neurons that contain choline acetyltransferase, neurons of the non-preganglionic Edinger-Westphal nucleus contain various neuropeptides, such as Urocortin and cocaine- and amphetamine-regulated transcript.[2] Previously, it had been proposed to rename this group of non-preganglionic, neuropeptide-containing neurons to perioculomotor subgriseal neuronal stream, abbreviated pIIISG.[3] However, more recently, a final nomenclature has been determined. Preganglionic oculomotor neurons within the Edinger-Westphal nucleus ...

Aminoacetonitrile - WikipediaAminoacetonitrile - Wikipedia

H2O The aminoacetonitrile can be hydrolysed to give glycine: Aminoacetonitrile derivatives are useful antihelmintics. They act ... In 2008, aminoacetonitrile was discovered in the Large Molecule Heimat, a giant gas cloud near the galactic center in the ... Aminoacetonitrile is a simple organic compound containing both nitrile and amino groups. It is somewhat similar to the simplest ... Industrially aminoacetonitrile is produced from glycolonitrile by reaction with ammonia: HOCH2CN + NH3 → H2NCH2CN + ...
more infohttps://en.wikipedia.org/wiki/Aminoacetonitrile

Aminoacetonitrile Nitrile Amine PNG  - PicpngAminoacetonitrile Nitrile Amine PNG - Picpng

... you can Download free Aminoacetonitrile Nitrile Amine png photos as transparent and share with your friends. - ... Aminoacetonitrile Nitrile Amine png image file has been added to the Aminoacetonitrile category by Bernadette OKeefe at size ... Aminoacetonitrile Nitrile Amine png image file has been added to the Aminoacetonitrile category by Bernadette OKeefe at size ... of 251258, 915x1280 resolution, you can Download free Aminoacetonitrile Nitrile Amine png photos as transparent and share with ...
more infohttps://www.picpng.com/image/aminoacetonitrile-nitrile-amine-png-69841

Anthelmintic - WikipediaAnthelmintic - Wikipedia

This is especially true of nematodes, and has helped spur development of aminoacetonitrile derivatives for treatment against ... effective against a variety of gastrointestinal helminths Aminoacetonitrile derivatives e.g., Monepantel : effective against a ...
more infohttps://en.wikipedia.org/wiki/Anthelmintic

Simple Accordion with CSS & jQuery by Soh TanakaSimple Accordion with CSS & jQuery by Soh Tanaka

Glycine hydrochloride can be prepared by the action of hydrochloric acid on hippuric acid,1 aminoacetonitrile,2 ... of water in a 1-l. beaker is added, in portions, 61.6 g. (0.4 mole) of aminoacetonitrile hydrogen sulfate at such a rate that ... 3. If the initial temperature of the acid mixture is below that indicated, there is a tendency for the aminoacetonitrile ... 4. The mother liquor contains a further quantity of aminoacetonitrile hydrogen sulfate which cannot, however, be recovered as ...
more infohttp://www.orgsyn.org/demo.aspx?prep=CV1P0298

Industrial Chemicals in Bhiwandi, Maharashtra | Suppliers, Dealers & Retailers of Industrial ChemicalsIndustrial Chemicals in Bhiwandi, Maharashtra | Suppliers, Dealers & Retailers of Industrial Chemicals

Find here Industrial Chemicals manufacturers, suppliers & exporters in Bhiwandi, Maharashtra. Get contact details & address of companies manufacturing and supplying Industrial Chemicals in Bhiwandi, Maharashtra.
more infohttps://dir.indiamart.com/bhiwandi/industrial-chemicals-all.html

Exhibitors | Page 7 | CPhI ChinaExhibitors | Page 7 | CPhI China

Aminoacetonitrile hydrochloride?6011-14-9?,1,3-Dimethyladamantane?702-79-4?,1-Bromo-3,5-dimethyladamantane?941- ...
more infohttps://www.cphi.com/china/exhibitors/grid?page=6

Combi-BlocksCombi-Blocks

N-(Diphenylmethylene)aminoacetonitrile. Purity: 98%. [70591-20-7], MFCD00009970. QA-2671. Diphenylmethylene-glycine benzyl ...
more infohttps://www.combi-blocks.com/blocks/CA39.htm

Search ResultsSearch Results

Bogey, M.; Dubus, H.; Guillemin, J.C., The millimeter-wave spectrum of aminoacetonitrile, J. Mol. Spectrosc., 1990, 143, 180-2 ...
more infohttps://webbook.nist.gov/cgi/cbook.cgi?Author=Bogey%2C+M.&Units=CAL&Mask=800

The genome and developmental transcriptome of the strongylid nematode Haemonchus contortus | Genome Biology | Full TextThe genome and developmental transcriptome of the strongylid nematode Haemonchus contortus | Genome Biology | Full Text

... an aminoacetonitrile derivative; AAD) [7]. Importantly, in the H. contortus gene set, we found a homolog acr-23 of the C. ...
more infohttps://genomebiology.biomedcentral.com/articles/10.1186/gb-2013-14-8-r89

Resistance status of drench groupsResistance status of drench groups

Amino-acetonitrile derivative (AAD). Resistance to this group is still unknown in Australia. So far, there is no claim for ...
more infohttp://www.wormboss.com.au/tests-tools/management-tools/drench-resistance/resistance-status-of-drench-groups.php

ethyl formateethyl formate

our publication on aminoacetonitrile (Belloche et al. 2008, A&A, 482, 179). suggests that the abundance of glycine, if present ... because the same team use the same data lasts year to reveal that the same galactic gas cloud also contains aminoacetonitrile. ...
more infohttps://www.sciencebase.com/science-blog/tag/ethyl-formate

Amphetaminil - wikidocAmphetaminil - wikidoc

2-phenyl-2-(1-phenylpropanyl-2-amino)acetonitrile. CAS Number. *17590-01-1 ...
more infohttps://www.wikidoc.org/index.php/Amphetaminil

Inhibitors of IAP - Genentech, Inc.Inhibitors of IAP - Genentech, Inc.

3-Aryl-4-aminoimidazoles such as 3-phenyl-3H-imidazol-4-ylamine may be prepared by reacting phenylamine with aminoacetonitrile ... Chem., 1981, 46:856-9 and illustrated in scheme 3 below by reacting phenylamine with aminoacetonitrile. ...
more infohttp://www.freepatentsonline.com/8110568.html

Hepatic Fibrosis and Cirrhosis | SpringerLinkHepatic Fibrosis and Cirrhosis | SpringerLink

Fiume L. Inhibition by aminoacetonitrile of early lesions induced in the liver of rats by carbon tetrachloride. J Pathol ... Fiume L, Favilli G. Inhibition of experimental cirrhosis by carbon tetrachloride following treatment with aminoacetonitrile. ...
more infohttps://link.springer.com/chapter/10.1007/978-1-4419-7107-4_30

WO2011035945A2 - Use of a combination of carnitine and/or a carnitine derivative with purine and/or a purine derivative for...WO2011035945A2 - Use of a combination of carnitine and/or a carnitine derivative with purine and/or a purine derivative for...

Purine can be made for example of amino acetonitrile and formamide. Purines and purine derivatives are often isolated from ...
more infohttps://patents.google.com/patent/WO2011035945A2/en

DE102011077950A1 - Cosmetic, non-therapeutic use of purine and/or its derivative to reduce the formation of reactive oxygen...DE102011077950A1 - Cosmetic, non-therapeutic use of purine and/or its derivative to reduce the formation of reactive oxygen...

Purine can be made for example of amino acetonitrile and formamide. Purine und Purinderivate werden oft aus Naturstoffen ...
more infohttps://patents.google.com/patent/DE102011077950A1/en

Publikationen - Universität InnsbruckPublikationen - Universität Innsbruck

Formation of Negative Ions upon Dissociative Electron Attachment to the Astrochemically Relevant Molecule Aminoacetonitrile.. ...
more infohttps://www.uibk.ac.at/ionen-angewandte-physik/ag-denifl/publikationen.html.de

US Patent # 5,610,165. N-acylpiperidine tachykinin antagonists - Patents.comUS Patent # 5,610,165. N-acylpiperidine tachykinin antagonists - Patents.com

a) N-(2-Methoxybenzyl)--N-(methyl)aminoacetonitrile A mixture of 2.0 g (13.2 mmole) of N-methyl-2methoxybenzylamine, 0.99 g ( ... aminoacetonitrile in 20 mL of diethyl ether. The mixture was heated at reflux for 1 hour and then was allowed to cool to room ...
more infohttp://www.patents.com/us-5610165.html

CiNii Articles - ICHIDA FUMIHIROCiNii Articles - ICHIDA FUMIHIRO

The Therapeutic Effect of N-[N-(4-Carboxyphenyl) glycyl]-aminoacetonitrile on Chronic Hepatitis (Active Form)-A Double Blind ...
more infohttps://ci.nii.ac.jp/author?q=ICHIDA+FUMIHIRO&sortorder=1&count=20&start=41

Slowing Dewormer Resistance «  Kaeco Group, Inc.  |  Animal Care products for Horses, Cattle, Goats, Dogs, Cats, Birds and...Slowing Dewormer Resistance « Kaeco Group, Inc. | Animal Care products for Horses, Cattle, Goats, Dogs, Cats, Birds and...

It is the first anthelmintic in a new class of anthelmintics called Amino-Acetonitrile Derivatives (ADD). Zolvix® is effective ...
more infohttp://www.kaeco.com/slowing-dewormer-resistance/

1R)-2-[(cyanomethyl)amino]-1-(\{[2-(difluoromethoxy)benzyl]sulfonyl\}methyl)-2-oxoethyl morpholine-4-carboxylate - Ontology...1R)-2-[(cyanomethyl)amino]-1-(\{[2-(difluoromethoxy)benzyl]sulfonyl\}methyl)-2-oxoethyl morpholine-4-carboxylate - Ontology...

2-bromo-4-methylphenyl)\{6-[(4-\{[3-(dimethylamino)-2-hydroxypropyl]oxy\}phenyl)amino]pyrimidin-4-yl\}amino)acetonitrile + ... 2-chloro-5-methylphenyl)\{6-[(4-\{[(2R)-3-(dimethylamino)-2-hydroxypropyl]oxy\}phenyl)amino]pyrimidin-4-yl\}amino]acetonitrile ...
more infohttps://rgd.mcw.edu/rgdweb/ontology/view.html?acc_id=CHEBI:44189